In the phase III randomized PROFILE 1014 trial, crizotinib, administered to treatment‐naive patients with ALK‐positive advanced nonsquamous NSCLC, demonstrated superior efficacy compared with first‐line chemotherapy [23]. This evidence concerns the gene ALK and non-small cell lung carcinoma.